Inventor
STRUTHERS MARY
US12 patents
Patents
12 patentsUS11220550B2Jan 11, 2022
Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
BRISTOL MYERS SQUIBB CO12 citations85
US11926673B2Mar 12, 2024
Antagonistic CD40 monoclonal antibodies and uses thereof
BRISTOL MYERS SQUIBB CO4 citations84
US11254750B2Feb 22, 2022
Antagonistic CD40 monoclonal antibodies and uses in treating immune responses
BRISTOL MYERS SQUIBB CO6 citations84
US11359000B2Jun 14, 2022
Interleukin-2/Interleukin-2 receptor alpha fusion proteins and methods of use
BRISTOL MYERS SQUIBB CO5 citations79
US10787494B2Sep 29, 2020
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
BRISTOL MYERS SQUIBB CO8 citations79
US12419953B2Sep 23, 2025
Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodies
BRISTOL MYERS SQUIBB CO1 citations73
US11613585B2Mar 28, 2023
Nucleic acids encoding antagonistic CD40 monoclonal antibodies
BRISTOL MYERS SQUIBB CO3 citations72
US11795231B2Oct 24, 2023
Antagonistic CD40 monoclonal antibodies and uses thereof
BRISTOL MYERS SQUIBB CO2 citations71
US11773178B2Oct 3, 2023
Antagonistic CD40 monoclonal antibodies and uses thereof
BRISTOL MYERS SQUIBB CO2 citations71
US11261258B2Mar 1, 2022
Antagonistic CD40 monoclonal antibodies and uses thereof
BRISTOL MYERS SQUIBB CO2 citations71
US12409223B2Sep 9, 2025
Antagonistic CD40 monoclonal antibodies and uses thereof
BRISTOL MYERS SQUIBB CO0 citations61
US12202872B2Jan 21, 2025
Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
BRISTOL MYERS SQUIBB CO0 citations58